 Denonimab is the second drug available for Alzheimer's patients with early symptoms. It will be sold under the brand name Kesunla, and it slowed cognitive decline overall by about 22% over 18 months. Google is backing off its climate emissions efforts. CBS News tech contributor Ian Shurer says he thinks he knows why.